PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT04388878
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20-valent pneumococcal conjugate vaccineBiological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1997
- Registration Number
- NCT04382326
- Locations
- 🇺🇸
Palmetto Pediatrics, PA, North Charleston, South Carolina, United States
🇺🇸Northwest Arkansas Pediatrics, Fayetteville, Arkansas, United States
🇺🇸Houston Clinical Research Associates, Houston, Texas, United States
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccineBiological: 20-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1511
- Registration Number
- NCT04379713
- Locations
- 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸Idaho Falls Pediatrics, Idaho Falls, Idaho, United States
🇭🇺Mimiped Bt, Gyor, Hungary
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- Drug: Immuno-oncology (IO)
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04375150
- Locations
- 🇺🇸
Pfizer INC, New York, New York, United States
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
- Conditions
- Hemophilia A
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT04370054
- Locations
- 🇺🇸
NOW Physical Therapy, Mountain View, California, United States
🇺🇸Clinical and Translational Research Unit (CTRU), Palo Alto, California, United States
🇺🇸Lucile Packard Childrens Hospital, Palo Alto, California, United States
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 391
- Registration Number
- NCT04360187
- Locations
- 🇯🇵
Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic, Kobe-City, Hyōgo, Japan
🇯🇵Miyata Dermatology Clinic, Matsudo City, Chiba, Japan
🇯🇵Chitose dermatology and plastic surgery clinic, Chitose Shi, Hokkaido, Japan
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT04362072
- Locations
- 🇺🇸
UCI Medical Center/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇮🇳Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, DEL, India
🇮🇳Bhakti Vedanta Hospital and Research Institute, Thane, Maharashtra, India
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT04355845
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
- Conditions
- Aplastic Anemia
- Interventions
- Biological: PF-06462700
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04350606
- Locations
- 🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04351334
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States